TITLE

Viral Load Decay in Antiretroviral-Naïve Patients Receiving Once-Daily Tenofovir and Emtricitabine plus Twice-Daily Nevirapine

AUTHOR(S)
Anthony Amoroso; Bruce Gilliam; Rohit Talwani; Colleen Boyce; Robert Redfield; Charles Davis
PUB. DATE
September 2009
SOURCE
HIV Clinical Trials;Sep2009, Vol. 10 Issue 5, p320
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: The once-daily nucleoside reverse transcriptase inhibitor backbone of tenofovir and emtricitabine has been proven effective in combination with efavirenz and protease inhibitors in large clinical trials. This study evaluated tenofovir and emtricitabine in combination with nevirapine. Methods: Viral load was assessed at baseline, Day 3, and Day 7 in addition to Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, and 84 in 10 antiretroviral-naïve patients participating in an open-label clinical trial of tenofovir and emtricitabine once daily in combination with nevirapine twice daily. Results: All patients achieved viral decay with this combination. Two patients discontinued prior to virologic suppression, one with a viral load of 55 copies/mL. Virologic suppression (Conclusion: In this study of treatmentnaïve patients, the combination of tenofovir and emtricitabine plus twice-daily nevirapine produced sustained viral load decay in patients including those with a high baseline viral load.
ACCESSION #
47471692

 

Related Articles

  • First-Line Nevirapine in Combination with Nucleoside Analogues Compared with Nevirapine Added to a Salvage HAART. Manfredi, R.; Chiodo, F. // Infection;Jun2000, Vol. 28 Issue 3, p167 

    Background: Although non-nucleoside reverse transcriptase inhibitors are presently recommended as a part of an initial triple antiretroviral regimen, or as an adjunct to a rescue therapy in patients with poor response to highly active antiretroviral therapy (HAART), no controlled data are...

  • Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. Landman, Roland; Capitant, Catherine; Descamps, Diane; Chazallon, Corine; Peytavin, Gilles; Katlama, Christine; Pialoux, Gilles; Bentata, Michelle; Brun-Vézinet, Francoise; Aboulker, Jean-Pierre; Yéni, Patrick // Journal of Antimicrobial Chemotherapy (JAC);Jul2009, Vol. 64 Issue 1, p118 

    Objectives We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients. Methods Thirty patients received...

  • A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients. Girard, Pierre-Marie; Cabié, André; Michelet, Christian; Verdon, Renaud; Katlama, Christine; Mercié, Patrick; Morand-Joubert, Laurence; Pétour, Pascal; Monchecourt, Françoise; Chêne, Geneviève; Trylesinski, Aldo // Journal of Antimicrobial Chemotherapy (JAC);Jul2009, Vol. 64 Issue 1, p126 

    Objectives To assess simplified maintenance regimens containing dual antiretroviral drugs in patients with controlled human immunodeficiency virus type 1 infection. Methods A non-inferiority, randomized, multicentre, open-label trial was performed in 24 AIDS clinical centres in France...

  • Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. Mosha, Fausta; Ledwaba, Johanna; Ndugulile, Faustine; Ng'ang'a, Zipora; Nsubuga, Peter; Morris, Lynn; Kasubi, Mabula; Swai, Andrew; Vercauteren, Jurgen; Vandamme, Anne-Mieke // Journal of Infection in Developing Countries;Jul2014, Vol. 8 Issue 7, p845 

    Introduction: In Tanzania, the follow-up on antiretroviral therapy (ART) response is based on clinical outcomes. We investigated virological response and ARV resistance mutations in relation to clinical response in ARV-treated patients. Methodology: A cross-sectional study of a cohort of 150...

  • Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A Randomized Trial. Saag, Michael S.; Cahn, Pedro; Raffi, François; Wolff, Marcelo; Pearce, Daniel; Molina, Jean-Michel; Powderly, William; Shaw, Audrey L.; Mondou, Elsa; Hinkle, John; Borroto-Esoda, Katyna; Quinn, Joseph B.; Barry, David W.; Rousseau, Franck // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p180 

    Context Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV). Objective To assess the efficacy and safety of emtricitabine as compared with stavudine when used with a background regimen of didanosine...

  • High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. D. Rey; B. Hoen; P. Chavanet; M. P. Schmitt; G. Hoizey; P. Meyer; G. Peytavin; B. Spire; C. Allavena; M. Diemer; T. May; J. L. Schmit; M. Duong; V. Calvez; J. M. Lang // Journal of Antimicrobial Chemotherapy (JAC);Feb2009, Vol. 63 Issue 2, p380 

    : Background The combination of one non-nucleoside reverse transcriptase inhibitor (NNRTI) with two nucleoside reverse transcriptase inhibitors is a validated first-line antiretroviral (ARV) therapy. The once-daily combination of lamivudine, tenofovirDF and nevirapine has not been evaluated in a...

  • A Prospective, Randomized Trial of Structured Treatment Interruption for Patients with Chronic HIV Type 1 Infection. Cardiello, Peter G.; Hassink, Elly; Ananworanich, Jintanat; Srasuebkul, Preeyaporn; Samor, Lanka; Mahanontharit, Apicha; Ruxrunqtham, Kiat; Hirschel, Bernard; Lange, Joep; Phanuphak, Praphan; Cooper, David A. // Clinical Infectious Diseases;2/15/2005, Vol. 40 Issue 4, p594 

    Background. Structured treatment interruption was evaluated in 74 patients who had been retreated with antiretrovirals, consisting of 2 nucleoside reverse-transcriptase inhibitors (NRTIs) for 1 year followed by 3 years of highly active antiretroviral therapy containing a protease inhibitor....

  • Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study. Markowitz, Norman; Lopardo, Gustavo; Wentworth, Deborah; Gey, Daniela; Babiker, Abdel; Fox, Lawrence; Tavel, Jorge // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    Background: The Study of Aldesleukin with and without Antiretroviral Therapy (STALWART) was designed to evaluate whether intermittent IL-2 alone or with peri-cycle ART increased CD4+ cell counts (and so delayed initiation of ART) in HIV infected individuals having ≥300 CD4+ cells/mm³...

  • Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children.  // AIDS Research & Therapy;2011, Vol. 8, p40 

    The article reports on a study that examines the incidence rate of immunologic failure (IF) and virologic failure (VF) after first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Thai HIV infected children. It states clinical and laboratory parameter...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics